U.S. Health Agencies Redirect $95 Million to Accelerate Human-Based Biomedical Research

On September 21, 2026, the National Institutes of Health allocated $88 million to 10 construction projects across the United States, explicitly directing the funds toward facilities designed for human-based research methodologies. The grants represent the financial anchor of a broader policy shift announced the same day by the Department of Health and Human Services (HHS), which rolled out more than 20 initiatives aimed at moving federal biomedical science away from animal testing.[1][2]

Before a new compound can be tested in human clinical trials, researchers must determine its toxicity and efficacy. Historically, this required administering the drug to animal models—often mice, dogs, or non-human primates—and observing the physiological response. However, because a mouse's metabolic pathways and cellular receptors differ fundamentally from a human's, these models frequently fail to predict how a drug will actually behave in patients. To solve this biological translation problem, scientists have developed New Approach Methodologies (NAMs). These include organ-on-a-chip devices, which use microfluidic channels lined with living human cells to simulate the mechanical and chemical environment of entire organs, allowing researchers to observe human-specific cellular responses in real time.[4]

The newly announced NIH funding is designed to build the physical infrastructure required to scale these technologies. Alongside the $88 million in construction grants, the agency launched a $7 million challenge to develop quantum-enabled sensing systems capable of measuring biological signals in lab-based NAMs. Furthermore, the NIH Clinical Center will house a new Bio Genesis Autonomous Human Biology Laboratory, which will integrate standardized organoids, robotics, and artificial intelligence into a closed-loop experimental platform.[1][2]

"NIH is building the scientific infrastructure needed to develop, validate, and scale technologies that better reflect human biology," said NIH Director Jay Bhattacharya. The goal, he noted, is to provide researchers with tools that can translate discoveries into treatments more reliably than current methods allow.[1][2]

The push extends beyond the NIH. HHS Secretary Robert F. Kennedy Jr. stated that the department is modernizing outdated regulations and breaking down barriers that have kept researchers dependent on animal models when better tools are available.[2]

In parallel, the Food and Drug Administration (FDA) issued a direct final rule updating its regulations to remove language that previously suggested animal testing was the only acceptable way to generate safety data for regulatory decisions. This aligns agency rules with the FDA Modernization Act of 2022, which legally recognized modern technologies as viable alternatives to animal trials.[2][3]

Animal welfare organizations, which have long lobbied for these changes, welcomed the announcements. Animal Wellness Action praised the FDA for stripping out archaic language that contradicted modern technological capabilities, noting that federal drug-screening regulations now formally recognize human cell-based systems and sophisticated computer models.[3]

While the federal government is heavily incentivizing the transition, the complete replacement of animal models remains a distant target. The FDA noted that its rule change does not eliminate or prohibit animal studies, as current alternative technologies cannot yet replicate every aspect of a living, complex biological system. To track the transition, the NIH has issued a request for information from the scientific community to assess the feasibility of publishing an annual report on the number of vertebrate animals still used in federally funded labs.[1][2]